07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Ibudilast regulatory update

MediciNova said FDA granted Fast Track designation for ibudilast to treat methamphetamine dependence. The phosphodiesterase-4 (PDE-4) , leukotriene B4 receptor and nitric oxide (NO) synthase inhibitor is in an investigator-led Phase II trial for the...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

Ibudilast: Phase IIa started

MediciNova began a placebo-controlled, U.S. Phase IIa trial to evaluate 100 mg/day ibudilast in about 24 healthy abusers of prescription opioids or heroin. NIH's National Institutes on Drug Abuse (NIDA) is funding the trial. The...
07:00 , Sep 17, 2012 |  BC Week In Review  |  Clinical News

Ibudilast: Phase II start

Early next year, MediciNova will begin a 12-week, placebo-controlled, U.S. Phase II trial to evaluate 100 mg daily ibudilast in 140 patients, including about 70 HIV-positive patients. The Center for Behavioral and Addition Medicine at...
07:00 , Apr 14, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Phosphodiesterase-4 (PDE-4); cyclic adenosine monophosphate (cAMP) A study in cell culture suggests that inhibiting the cAMP-specific PDE-4 may help treat Ras-dependent melanomas. In Ras-mutated...
08:00 , Dec 10, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Bone repair; osteoporosis Leukotriene B4 receptor (LTB4R; BLT1) A study in mice suggests that inhibiting BLT1 signaling could help prevent bone loss. In Blt1-deficient...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Company News

Avigen, Baxter, MediciNova deal

MediciNova disclosed that it made an unsolicited offer to acquire Avigen for 1.8 million shares and a convertible security equal to Avigen's net cash, less $7 million that would go to MediciNova. The shares are...
02:04 , Dec 24, 2008 |  BC Extra  |  Company News

MediciNova bids for Avigen

On Tuesday, MediciNova (NASDAQ:MNOV; Osaka:4875) disclosed that it made an unsolicited offer on Monday to acquire Avigen (NASDAQ:AVGN) for 1.8 million shares and a convertible security equal to Avigen's net cash, less $7 million. The...
08:00 , Nov 17, 2008 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 11/14 cls Advanced Life (NASDAQ:ADLS) Susquehanna Angela Larson Price target Net positive -21% $0.23 Larson lowered her target to $2 from $2.50. She noted...
07:00 , Apr 14, 2008 |  BC Week In Review  |  Clinical News

Ibudilast: Additional Phase II data

Two-year data from a 297-patient Phase II trial showed that the high dose of oral MN-166 (60 mg/day) significantly reduced brain volume loss vs. placebo. Also, the risk of disability progression was significantly less in...
07:00 , Apr 7, 2008 |  BC Week In Review  |  Clinical News

Ibudilast: Additional Phase II data

Additional data from the first year of a 2-year Phase II trial showed that oral MN-166 significantly decreased the progression of new inflammatory lesions to persistent black holes, which MediciNova said are brain lesions that...